Assertio Holdings Interest Expense 2011-2026 | ASRT

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Assertio Holdings

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.78 M	-278 K	10.2 M	15.9 M	58.4 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
58.4 M	-278 K	17.4 M

Quarterly Interest Expense Assertio Holdings

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	45 K	8 K	716 K	-	-467 K	11 K	802 K	-	2 K	-95 K	2.33 M	-	2.5 M	2.6 M	2.68 M	-	3.05 M	1.6 M	8.67 M	-	13.9 M	14.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.8 M	-467 K	3.13 M

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.07	-0.47 %	$ 115 M	Canada
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Harrow Health HROW	47 K	$ 38.95	-27.32 %	$ 1.43 B	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	27.4 K	$ 0.55	-0.97 %	$ 9.61 M	China
Cumberland Pharmaceuticals CPIX	606 K	$ 4.5	-7.02 %	$ 63.3 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Organogenesis Holdings ORGO	20 K	$ 2.86	-4.67 %	$ 377 M	USA
Emergent BioSolutions EBS	87.9 M	$ 8.87	-1.33 %	$ 454 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Rockwell Medical RMTI	2.3 M	$ 0.9	0.37 %	$ 21 M	USA
Evolus EOLS	-539 K	$ 4.21	-1.86 %	$ 261 M	USA
Bausch Health Companies BHC	-28 M	$ 5.77	-3.11 %	$ 2.11 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Perrigo Company plc PRGO	-13.2 M	$ 11.38	-7.97 %	$ 1.58 B	USA
Sundial Growers SNDL	81 K	$ 1.53	0.33 %	$ 3.37 M	Canada
Pacira BioSciences PCRX	-373 K	$ 22.06	3.67 %	$ 1.02 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.67	-3.51 %	$ 141 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.73	-2.19 %	$ 34.9 M	USA
Solid Biosciences SLDB	652 K	$ 5.99	-3.47 %	$ 244 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 2.76	-2.66 %	$ 3.43 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
TherapeuticsMD TXMD	300 K	$ 2.26	1.0 %	$ 23.6 M	USA
Tilray TLRY	46.6 M	$ 7.37	-2.97 %	$ 4.55 B	Canada
Veru VERU	862 K	$ 2.54	-3.05 %	$ 343 M	USA
Viatris VTRS	573 M	$ 15.09	-3.89 %	$ 18.1 B	USA
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA
cbdMD YCBD	-29.5 K	$ 0.79	-2.48 %	$ 3.41 M	USA